QuikChange II XL Site-Directed Mutagenesis Kit, 10 Rxn

Site Directed Mutagenesis (SDM) Mouse - Point mutation Neuro 2a proglucagon

Experiment
Site Directed Mutagenesis (SDM) Mouse - Point mutation Neuro 2a proglucagon
Product
QuikChange II XL Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies
Manufacturer
Agilent Technologies

Protocol tips

Protocol tips
- Use only the Dpn I enzyme provided; do not substitute with an enzyme from another source.

Publication protocol

Cell culture, plasmids and transfections
Wild-type Neuro 2a (N2a wt) cells and Neuro 2a cells stably transfected with mouse Cpe (N2a-CPE, clone 17) were obtained from Dr Y P Loh (Bethesda, MD, USA). Cells were maintained in DMEM containing 10% FBS and stable transfectants were maintained in media containing 400 μg/ml G418. N2a wt cells were also stably transfected with the enzymatically inactive form of CPE, E300Q (Qian et al. 1999) using Lipofectamine 2000 (Invitrogen). Stable transfectants were selected in 800 μg/ml G418, pooled and maintained in 400 μg/ml G418. To examine the role of CPE in sorting proglucagon, N2a wt, N2a-CPE and N2a-E300Q cells were transfected with hamster pre-proglucagon (in pcDNA 3.1; a kind gift from Dr D F Steiner, Chicago, IL, USA). To examine the roles of other prohormone convertases, both N2a wt and N2a-CPE cells were transiently transfected with plasmids encoding PC1/3 and PC2 (kind gifts from Dr N G Seidah, Montreal, QC, Canada). To determine possible sorting signals, the sequence of proglucagon was mutated independently at three sites: at the processing site, R70K71; at the dibasic site within glucagon, R17R18; and at two leucines that were postulated to flank the helix structure within glucagon, L14 and L26. The processing site mutant, K71Q, was a kind gift from Dr D F Steiner (Chicago, IL, USA). We generated the mutation at the dibasic site, R18Q (forward primer sequence 5′-AAATACCTGGACTCCCGCCAAGCCCAAGAT-3′), and the double leucine-to-proline mutation was done in two steps; L14P was made using forward primer 1, 5′-TACAGCAAATACCCGGACTCCCGCCGAGCC-3′; and L26P was subsequently generated using forward primer 2, 5′-CAAGATTTTGTGCAGTGGCCGATGAACACC-3′. Bold sequences in primers indicate site of mutation. All site-directed mutagenesis reactions were carried out using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) and results were confirmed by sequencing at the London Regional Genomics Facility, University of Western Ontario.



Full paper   Login or join for free to view the full paper.

Reviews

QuikChange II XL Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing Site Directed Mutagenesis (SDM) Mouse - Point mutation Neuro 2a proglucagon using QuikChange II XL Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies.

Paper title
The sorting of proglucagon to secretory granules is mediated by carboxypeptidase E and intrinsic sorting signals.
Full paper
Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Agilent Technologies for QuikChange II XL Site-Directed Mutagenesis Kit, 10 Rxn below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing Site Directed Mutagenesis (SDM) Mouse - Point mutation Neuro 2a proglucagon using QuikChange II XL Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms